Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans

European Journal of Heart Failure

Volumn 5, Issue 3, 2003, Pages 391-398

  Cleland, John G F ^a   Coletta, Alison P ^a   Nikitin, Nikolay ^a   Louis, Amala ^a   Clark, Andrew ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

ASCOT; COMPANION; EPHESUS; SPORTIF III; T Wave Alternans; UK PACE

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; STATINE; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PACING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

ALDOSTERONE ANTAGONISTS; ANTICOAGULANTS; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PACEMAKER, ARTIFICIAL; SPIRONOLACTONE; VENTRICULAR DYSFUNCTION, LEFT; WARFARIN;

EID: 0042035675     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(03)00057-6     Document Type: Article

References (25)

1. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2003;15(1):79-87.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-21.
3. Struthers AD. Mineralocorticoid receptor blockade in chronic heart failure. J Hum Hypertens 1995;9(6):443-6.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341(10):709-17.
5. The SOLVD Investigators. Effect on enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
6. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999;1:41-5.
7. Cleland JGF, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomised clinical trials. Eur Heart J 1996;17:674-81.
8. Khand A, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000;21:614-32.
9. Cleland JGF. Is aspirin 'The Weakest Link' in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002;44:275-92.
10. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opinion Cardiol 1997;12:276-87.
11. Sever P, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
12. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROPSER): a randomised controlled trial. Lancet 2002;360:1623-30.
13. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. For the Multicenter Automatic Defibrillator Implantation Trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346(12):877-83.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Am Med Assoc 2002;288:2998-3007.
15. Coletta A, Nikitin N, Clark AL, Cleland JGF. Clinical trials update from the American Heart Association meeting: PROSPER, DIAL home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure. Eur J Heart Fail 2003;5(1):95-9.
16. Louis A, Cleland JGF, Crabbe S, Ford S, Thackray S, Houghton T, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-7.
17. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39(10):1567-73.
18. Bristow MR, Feldman AM, Saxon LA. For the Companion Steering Committee and Companion Clinical Investigators. Heart Failure Management Using Implantable Devices for Ventricular Resynchronization: Comparison of Medical Therapy, Pacing and Defibrillation in Chronic Heart Failure (COMPANION) trial. J Card Fail 2000;6(3):276-85.
19. Cleland JGF, Ghosh J, Khan NK, Ghio S, Tavazzi L, Kaye G. Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony? Eur Heart J 2003;24(5):384-90.
20. Cleland JGF, Thackray S, Goodge L, Kaye GC, Cooklin M. Outcome studies with device therapy in patients with heart failure. J Cardiovasc Electrophysiol 2002;13:S73-S91.
21. Cleland JGF, Kappenberger LJ, Tavazzi L, Klein W, Erdmann E. Design and methodology of the CARE-HF trial. A randomised trial of cardiac resynchronisation in patients with heart failure and ventricular dyssynchrony. Eur J Heart Fail 2001;3:481-9.
22. Lamas GA, Orav J, Stambler BS, Ellenbogen KA, Sgarbossa EB, Huang SKS, et al. for the Pacemaker Selection in the Elderly Investigators. Quality of life and clinical outcomes in elderly patients being treated with ventricular pacing as compared with dual-chamber pacing. N Engl J Med 1998;338:1097-104.
23. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, et al. For the Canadian Trial of Physiologic Pacing Investigators. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med 2000;342(19):1385-91.
24. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. J Am Med Assoc 2002;288(24):3115-23.
25. Klingenheben T, Zabel M, D'Agostino RB, Cohen RJ, Hohnloser SH. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. Lancet 2000;356:651-1.